In vivo and in vitro glycogenic effects of methionine sulfoximine are different in two inbred strains of mice.
We investigated the relationship between brain glycogen anabolism and methionine sulfoximine (MSO)-induced seizures in two inbred mouse strains that presented differential susceptibility to the convulsant. CBA/J was considered a MSO-high-reactive strain and C57BL/6J a MSO-low-reactive strain. Accordingly, the dose of MSO needed to induce seizures in CBA/J mice is lower than that in C57BL/6J mice, and CBA/J mice which had seizures, died during the first convulsion. In addition, the time--course of the MSO effect is faster in CBA/J mice than that in C57BL/6J mice. Analyses were performed in C57BL/6J and CBA/J mice after administration of 75 (subconvulsive dose) and 40 mg/kg of MSO (subconvulsive dose, not lethal dose), respectively. In the preconvulsive period, MSO induced an increase in the brain glycogen content of C57BL/6J mice only. Twenty-four hours after MSO administration, the brain glycogen content increased in both strains. The activity and expression of fructose-1,6-bisphosphatase, the last key enzyme of the gluconeogenic pathway, were increased in MSO-treated C57BL/6J mice as compared to control mice, at all experimental time points, whereas they were increased in CBA/J mice only 24 h after MSO administration. These latter results correspond to CBA/J mice that did not have seizures. Interestingly, the differences observed in vivo were consistent with results in primary cultured astrocytes from the two strains. This data suggests that the metabolism impairment, which was not a consequence of seizures, could be related to the difference in seizure susceptibility between the two strains, depending on their genetic background.
Bernard-Hélary
Katy
K
Métabolisme Cérébral et Neuropathologies, UPRES EA 2633, Université d'Orléans, Enceinte du Château, Bâtiment 23, Avenue du Parc Floral, BP 6759, 45067 Orléans CEDEX 2, France.
Ardourel
Marie-Yvonne
MY
Hévor
Tobias
T
Cloix
Jean-François
JF
D000818:Animals; D001253:Astrocytes / Q000378:metabolism; D002478:Cells, Cultured; D003292:Convulsants / Q000008:administration & dosage / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006597:Fructose-Bisphosphatase / Q000235:genetics / Q000378:metabolism; D005943:Gluconeogenesis; D006003:Glycogen / Q000096:biosynthesis* / Q000378:metabolism; D008717:Methionine Sulfoximine / Q000008:administration & dosage / Q000494:pharmacology*; D051379:Mice; D008810:Mice, Inbred C57BL / Q000378:metabolism*; D008808:Mice, Inbred CBA / Q000378:metabolism*; D009994:Osmolar Concentration; D012333:RNA, Messenger / Q000378:metabolism; D012640:Seizures / Q000139:chemically induced / Q000378:metabolism; D013045:Species Specificity; D013997:Time Factors
D003292:Convulsants; D012333:RNA, Messenger; D008717:Methionine Sulfoximine; D006003:Glycogen; D006597:Fructose-Bisphosphatase